| Literature DB >> 35590084 |
Seyedeh-Leili Asadi-Yousefabad1, Pegah Nammian2, Mohammad Hasan Sheikhha3,4, Seyed Mohammad Bagher Tabei5,6, Sajad Daneshi7, Habib Nikukar8, Marzieh Lotfi9, Vahid Razban10,11.
Abstract
The aim of this research is to compare the capabilities of Adipose tissue mesenchymal stem cells (AT-MSCs) and bone marrow mesenchymal stem cells (BM-MSCs) in the treatment of diabetic male mice with CLI model. Supernatants were collected from C57BL/6 mice isolated AT-MSCs and BM-MSCs, afterward their effects on human umbilical vein endothelial (HUVEC) migration potential were evaluated. Diabetes mellitus type 1 was induced by streptozotocin injection. Diabetic mice with CLI model were divided into three groups and injected with AT-MSCs, BM-MSCs, or PBS then the efficacy of them was assessed. Survival of MSCs was analysed by SRY-specific gene. The conditioned medium of AT-MSCs and BM-MSCs stimulated HUVECs migration and the donor cells were detected till 21 day in two groups. BM-MSCs and AT-MSCs improved significantly functional recovery and ischemia damage. Neovascularization in ischemic muscle was significantly higher in mice treated with AT-MSCs and BM-MSCs and they improved muscle regeneration. In vivo and in vitro findings show that AT-MSCs and BM-MSCs transplantation could be proposed as a promising therapy to promote angiogenesis and muscle regeneration through secretion of proangiogenic factors, cytokines and growth factors in diabetic mice with CLI model wherein blood supply is insufficient and disrupted.Entities:
Keywords: Adipose tissue-mesenchymal stem cells; Angiogenesis; Bone marrow-mesenchymal stem cells; Critical limb ischemia; Diabetes mellitus
Year: 2022 PMID: 35590084 DOI: 10.1007/s10561-022-10007-7
Source DB: PubMed Journal: Cell Tissue Bank ISSN: 1389-9333 Impact factor: 1.522